LHP588 is an oral, brain-penetrant lysine-gingipain (Kgp) inhibitor designed to block the key virulence factor of P. gingivalis
VYVGART was well tolerated, with a safety profile consistent with prior studies in AChR-Ab seropositive gMG and other indications
Protein L is known as a “superantigen” because it can bind antibodies in unusual ways
Dr. Reddy’s becomes the first pharmaceutical company to receive regulatory approval to launch Linaclotide in India under the brand name Colozo
The company is bringing precision therapies for gynaecological cancers
NATCO holds the first-to-file status for this product and will have 180-day generic drug exclusivity
The patient had been battling DFSP for over eight years, enduring multiple recurrences despite three previous surgeries
The technology offers scalable continuous granulation at 200 kg/hour, with the potential to exceed 500 kg/hour for certain granules
The collaboration will combine Firstsource’s AI-first approach with Guidehealth’s expertise in value-based care innovation
Subscribe To Our Newsletter & Stay Updated
